1 / 3

Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial

HORIZONS Trial. Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial. HORIZONS Trial: Study Design. 3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting

odell
Download Presentation

Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HORIZONS Trial Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial

  2. HORIZONS Trial: Study Design 3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting 1, 6, and 12 month follow-up for all patients undergoing primary randomization, angiography at 13 months for 1500 stent randomized patients only, yearly follow-up for 5 years for all patients. Antithrombotic Therapy Randomized 1:1 Bivalirudin + Bail-Out IIb/IIIa Inhibitor n=1700 UFH + IIb/IIIa Inhibitor n=1700 Target Vessel Stenting to DES vs BMS Randomized 3:1 • Hypothesis 1: Bivalirudin compared to UFH + routine IIb/IIIa will reduce the composite rate of death, reinfarction, TVR, stroke, and major bleeding at 30 days Presented at TCT 2005

  3. HORIZONS Trial: Study Design 3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting 1, 6, and 12 month follow-up for all patients undergoing primary randomization, angiography at 13 months for 1500 stent randomized patients only, yearly follow-up for 5 years for all patients. Antithrombotic Therapy Randomized 1:1 Target Vessel Stenting Randomized 3:1 TAXUS stent n=2250 Bare metal Express stent n=750 • Hypothesis 2: Use of polymer-based slow-release paclitaxel-eluting TAXUS stent will safely reduce the 1 year rate of ischemia-driven TLR Presented at TCT 2005

More Related